In our research, we found that rutaecarpine, but not evodiamine and dehydroevodiamine, can upregulate the expression of IL24 by activating the AhR signaling pathway, thereby inhibiting the migration of glioblastoma. The gene discussed is IL24; the disease is glioblastoma.